| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/17/2013 | US20130017163 Halogenated phenols for diagnostics, antioxidant protection and drug delivery |
| 01/17/2013 | US20130017156 Cefdinir and cefixime formulations and uses thereof |
| 01/17/2013 | US20130017153 Unit dosage of apadenoson |
| 01/17/2013 | US20130017149 Pharmaceutical compounds |
| 01/17/2013 | US20130014759 Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis |
| 01/17/2013 | DE19941675B4 2-Amino-bicyclo[3.1.0] hexan-2,6-dicarbonsäurederivate und ein Verfahren zu deren Herstellung 2-amino-bicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivatives and a process for their preparation |
| 01/17/2013 | CA2878259A1 Terpene analogues and uses thereof for treating neurological conditions |
| 01/17/2013 | CA2850089A1 Stable dosage forms of arterolane and piperaquine |
| 01/17/2013 | CA2849213A1 Combination als therapy |
| 01/17/2013 | CA2844150A1 Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers |
| 01/17/2013 | CA2843777A1 Polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |
| 01/17/2013 | CA2843773A1 Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |
| 01/17/2013 | CA2842060A1 Method for the prevention and treatment of sepsis |
| 01/17/2013 | CA2841983A1 Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators |
| 01/17/2013 | CA2841972A1 Terpene analogues and uses thereof for treating neurological conditions |
| 01/17/2013 | CA2841932A1 4 - piperidinyl compounds for use as tankyrase inhibitors |
| 01/17/2013 | CA2841897A1 Novel compound having parp inhibitory activity |
| 01/17/2013 | CA2841864A1 Novel anti-cancer isocarbostyril alkaloid conjugates |
| 01/17/2013 | CA2841859A1 N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio)pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator |
| 01/17/2013 | CA2841807A1 A new therapeutical composition containing apomorphine as active ingredient |
| 01/17/2013 | CA2841731A1 Nicotinamide compositions and the therapeutic use thereof |
| 01/17/2013 | CA2841632A1 Gel compositions of oxymetazoline and methods of use |
| 01/17/2013 | CA2841540A1 Inhibitors of bacterial type iii secretion system |
| 01/17/2013 | CA2841487A1 Inhibitors of bacterial type iii secretion system |
| 01/17/2013 | CA2841411A1 Use of xanthophyll carotenoids to improve visual performance and neural efficiency |
| 01/17/2013 | CA2841272A1 Formulations of amikacin and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis |
| 01/17/2013 | CA2841239A1 Probiotic for administration to healthy young mammals during the weaning period for improving tolerance to newly introduced food stuffs |
| 01/17/2013 | CA2841238A1 Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors |
| 01/17/2013 | CA2841169A1 Orvinol and thevinol derivatives useful in the treatment of drug and alcohol abuse |
| 01/17/2013 | CA2841117A1 Method of treating atherosclerosis in high triglyceride subjects |
| 01/17/2013 | CA2841113A1 Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| 01/17/2013 | CA2841111A1 Novel pyrrolo pyrimidine derivatives |
| 01/17/2013 | CA2841108A1 New crystalline form |
| 01/17/2013 | CA2841095A1 Spiro compounds as hepatitis c virus inhibitors |
| 01/17/2013 | CA2841080A1 Inhibitors of bruton's tyrosine kinase |
| 01/17/2013 | CA2841032A1 Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
| 01/17/2013 | CA2840445A1 Thiophen-2-carboxylic acid derivatives useful as inhibitors of flaviviridae viruses |
| 01/17/2013 | CA2840401A1 Process for the preparation of fluticasone propionate form 1 |
| 01/17/2013 | CA2840217A1 (thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl compounds as dual activity h1 inverse agonists/5-ht2a antagonists |
| 01/17/2013 | CA2839844A1 Pharmaceutical composition for neurological disorders |
| 01/17/2013 | CA2839760A1 Use of oligosaccharide compounds for the prevention and treatment of pathological scars |
| 01/17/2013 | CA2839747A1 Eosinophil peroxidase compositions and methods of their use |
| 01/17/2013 | CA2839395A1 Aminomethyl quinolone compounds |
| 01/17/2013 | CA2839357A1 Novel fxr (nr1h4) binding and activity modulating compounds |
| 01/17/2013 | CA2839351A1 Radiolabelled rotenone derivatives and their use in spect imaging |
| 01/17/2013 | CA2837787A1 Pharmaceutical composition, methods for treating and uses thereof |
| 01/17/2013 | CA2837529A1 Positive allosteric modulators of nicotinic acetylcholine receptor |
| 01/17/2013 | CA2836346A1 Treatment of excessive menstrual bleeding associated with uterine fibroids |
| 01/17/2013 | CA2823786A1 Materials for treating and preventing mucosa related disease |
| 01/16/2013 | EP2546654A2 Heroin detection by raman spectroscopy from impure compositions comprising an interfering fluorescent contaminant |
| 01/16/2013 | EP2546345A1 DNA encoding polypeptide involved in biosynthesis of herboxidiene |
| 01/16/2013 | EP2546255A1 Benzazepine compound |
| 01/16/2013 | EP2546254A1 Imidazo[4,5-C]pyridine compounds and methods of antiviral treatment |
| 01/16/2013 | EP2546253A1 Substituted dihydropyrazolones for the treatment of cardiovascular and hematological diseases |
| 01/16/2013 | EP2546252A1 Heteroaryl-substituted 1,3 dihydroindol-2-one derivatives and medicaments containing them |
| 01/16/2013 | EP2546251A1 Heteroaryl-substituted 1,3 dihydroindol-2-one derivatives and medicaments containing them |
| 01/16/2013 | EP2546250A1 Heteroaryl-substituted 1,3 dihydroindol-2-one derivatives and medicaments containing them |
| 01/16/2013 | EP2546249A1 5-Alkynyl-pyridines |
| 01/16/2013 | EP2546248A1 Crystal form H of imatinib mesylate |
| 01/16/2013 | EP2546247A1 Imatinib mesylate preparation procedure |
| 01/16/2013 | EP2546246A2 Compounds and methods for the treatment or prevention of flavivirus infections |
| 01/16/2013 | EP2546245A1 Antiprotozoal compound originating in coelenterata |
| 01/16/2013 | EP2546242A1 Cannabinoid receptor ligands |
| 01/16/2013 | EP2546241A1 Cannabinoid receptor ligands |
| 01/16/2013 | EP2546239A1 6-amino isoquinolins compounds and methods for making the same |
| 01/16/2013 | EP2546238A1 6-amino isoquinolins compounds and methods for making the same |
| 01/16/2013 | EP2546237A1 7-amino isoquinolins compounds and methods for making the same |
| 01/16/2013 | EP2546234A1 Nitrogeneous heterocyclic derivative and medicine containing the same as an active ingredient |
| 01/16/2013 | EP2546233A1 Hydrobenzamide derivatives as inhibitors of HSP90 |
| 01/16/2013 | EP2546232A1 Diphenyl Substituted Alkanes |
| 01/16/2013 | EP2546231A1 Alkylamine derivative |
| 01/16/2013 | EP2545964A1 Novel FXR (NR1H4) binding and activity modulating compounds |
| 01/16/2013 | EP2545941A1 Method for proliferating cardiomyocytes using micro-rna |
| 01/16/2013 | EP2545939A2 Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
| 01/16/2013 | EP2545925A1 Compositions comprising hyaluronic acid for treating and preventing mucosa related diseases |
| 01/16/2013 | EP2545924A1 Method for the prevention and treatment of sepsis. |
| 01/16/2013 | EP2545923A1 Antibacterial agents |
| 01/16/2013 | EP2545922A1 Treatment of excessive menstrual bleeding associated with uterine fibroids |
| 01/16/2013 | EP2545921A2 Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms |
| 01/16/2013 | EP2545920A1 Therapy for complications of diabetes |
| 01/16/2013 | EP2545919A1 Treatment of synucleinopathies |
| 01/16/2013 | EP2545918A1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| 01/16/2013 | EP2545917A1 Novel ep4 agonist |
| 01/16/2013 | EP2545916A1 Use of coumarin derivatives for the preparation of drugs for treating skin diseases |
| 01/16/2013 | EP2545915A1 2-amino-2-oxoethyl trans-3-[5-(6-methoxy-naphtalen-1-yl)-1,3-dioxan-2-yl]propyl-carbamate for use in the treatment of persistent cancer pain |
| 01/16/2013 | EP2545914A1 2-amino-2-oxoethyl trans-3-[5-(6-methoxy-naphtalen-1-yl)-1,3-dioxan-2-yl]propyl-carbamate for use in the treatment of persistent cancer pain |
| 01/16/2013 | EP2545913A1 Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis |
| 01/16/2013 | EP2545912A1 Ketoprofen-containing aqueous adhesive skin patch |
| 01/16/2013 | EP2545911A1 Use of Lipoteichoic Acid in the Treatment of Non-Encapsulated Cancer Cells |
| 01/16/2013 | EP2545910A1 Use of Lipoteichoic Acid in the treatment of cancer in an inflammatory state |
| 01/16/2013 | EP2545909A1 Combination of D-Amino Acids and Lipoteichoic Acid |
| 01/16/2013 | EP2545907A1 Aqueous wet granulation process for cross-linked polyallylamine polymers |
| 01/16/2013 | EP2545777A1 Isoxazoline compositions and their use as antiparasitics |
| 01/16/2013 | EP2545187A1 Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
| 01/16/2013 | EP2545065A2 Water-soluble phytosterol derivatives for reducing cholesterol and preparation thereof |
| 01/16/2013 | EP2545064A1 Carbon monoxide releasing rhenium compounds for medical use |
| 01/16/2013 | EP2545060A1 Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases |
| 01/16/2013 | EP2545058A2 Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| 01/16/2013 | EP2545057A1 Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd |
| 01/16/2013 | EP2545056A1 Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd |